Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,098 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Control Subjects Clear all

Conditions: Healthy
Interventions: STP206 or vehicle control; Drug
Lead sponsor: Leadiant Biosciences, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer
Interventions: neratinib, Placebo, Moxifloxacin; Drug · Other
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Atopic Disease (Including Allergic Conjunctivitis)
Interventions: Drug: AC-170 0.24%, AC-170 0%; Drug
Lead sponsor: Aciex Therapeutics, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Healthy Volunteers
Interventions: Placebo, teduglutide; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Typhoid Fever
Interventions: Ty800 (Salmonella typhi) Oral Vaccine; Biological
Lead sponsor: Avant Immunotherapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 5
States / cities: San Diego, California • Melbourne, Florida • Peoria, Illinois + 2 more

Conditions: Healthy Volunteers
Interventions: MORF-057, Placebo for MORF-057; Drug
Lead sponsor: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy Subjects
Interventions: Trans-Sodium Crocetinate, Placebo; Drug
Lead sponsor: Diffusion Pharmaceuticals Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Excessive Daytime Sleepiness
Interventions: ORX142 Tablets, Placebo Tablets; Drug · Other
Lead sponsor: Centessa Pharmaceuticals (UK) Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Lincoln, Nebraska • Eatontown, New Jersey • New York, New York

Conditions: Drug Safety
Interventions: Placebo, VIA-3196; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Hepatitis C Virus
Interventions: BMS-791325, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 20 Years to 49 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy
Interventions: AZD1305, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 45 Years · Male only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Healthy Volunteers, Autoimmune Disease
Interventions: LAD191, Placebo; Drug · Other
Lead sponsor: Almirall, S.A.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Miami, Florida • Philadelphia, Pennsylvania • San Antonio, Texas

Conditions: Healthy Volunteer
Interventions: AZD1722, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 19 Years to 65 Years
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Cypress, California

Conditions: Type 2 Diabetes Mellitus
Interventions: DSP-8658, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Volunteers
Interventions: BPN-14967, Placebo; Drug
Lead sponsor: Belite Bio, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Peptic Ulcers
Interventions: Celecoxib, Naproxen, ASA; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 605 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 23
States / cities: Anaheim, California • San Diego, California • Farmington, Connecticut + 19 more

Conditions: Healthy
Interventions: IW-1701, Placebo; Drug
Lead sponsor: Cyclerion Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Systemic Lupus Erythematosus, Healthy
Interventions: JNJ-55920839, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Birmingham, Alabama • Rochester, Minnesota • Durham, North Carolina

Conditions: Healthy
Interventions: FosD, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 45 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy
Interventions: Clopidogrel, Placebo, Omeprazole; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Hereditary Angioedema (HAE)
Interventions: Recombinant human C1 esterase inhibitor, Placebo, SHP623; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Long QT Syndrome
Interventions: GS-6615, Placebo to match GS-6615, Placebo to match dofetilide, Dofetilide; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Influenza A Virus, H1N1 Subtype
Interventions: Zanamivir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Serious Infections Due to Known or Suspected Gram-positive Pathogens
Interventions: TD-1607, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Austin, Texas

Search by objective public record fields.

Safety and Tolerability of STP206 in Healthy Adult Subjects

Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)

A Multi-Center Study Evaluating the Safety of AC-170 0.24%

Effect of Teduglutide on Gastric Emptying in Healthy Subjects

Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects

Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers

Safety and Efficacy of Trans Sodium Crocetinate (TSC) in Enhancing Tissue Oxygen Levels in Healthy Volunteers

A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age

Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects

Japanese Bridging Study Conducted in the United States

AZD1305 Single and Multiple Ascending Dose Study in Healthy Japanese and Caucasian Subjects

Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease

Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects

Safety, Pharmacokinetics and Pharmacodynamics of DSP-8658 in Patients With Type 2 Diabetes Mellitus and Healthy Adults

Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy Adults

Celebrex Low Dose ASA Study Examining the Incidence of Gastroduodenal Ulcers in a Healthy Population

A Trial of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Healthy Subjects

A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus

A Study to Assess the Safety, Tolerability, and Blood and Urine Drug Levels of Fostamatinib Disodium (FosD) in Healthy Japanese and White Subjects

Interaction Study of Clopidogrel 600/150 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects

Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects

Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults

Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days

TD-1607 SAD Study in Healthy Subjects